Cargando…

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

BACKGROUND: Oestrogen receptor-negative (ER−) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Legrier, Marie-Emmanuelle, Bièche, Ivan, Gaston, Julie, Beurdeley, Arnaud, Yvonnet, Vanessa, Déas, Olivier, Thuleau, Aurélie, Château-Joubert, Sophie, Servely, Jean-Luc, Vacher, Sophie, Lassalle, Myriam, Depil, Stéphane, C Tucker, Gordon, Fontaine, Jean-Jacques, Poupon, Marie-France, Roman-Roman, Sergio, Judde, Jean-Gabriel, Decaudin, Didier, Cairo, Stefano, Marangoni, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815803/ https://www.ncbi.nlm.nih.gov/pubmed/26695443 http://dx.doi.org/10.1038/bjc.2015.398

Ejemplares similares

Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
por: Gaston, Julie, et al.
Publicado: (2019)

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
por: Gaston, Julie, et al.
Publicado: (2016)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
por: de Plater, Ludmilla, et al.
Publicado: (2014)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft
por: Legrier, M-E, et al.
Publicado: (2004)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

Molecular profiling of patient-derived breast cancer xenografts
por: Reyal, Fabien, et al.
Publicado: (2012)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2020)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Nuclear DNA Content and Chromatin Pattern of Rat Rhabdomyosarcoma Cell Sublines with Different Metastatic Potentials
por: Dufer, Jean, et al.
Publicado: (2000)

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients
por: Karam, Manale, et al.
Publicado: (2014)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer
por: Tury, Sandrine, et al.
Publicado: (2016)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
por: Deniziaut, Gabrielle, et al.
Publicado: (2016)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype
por: Grassilli, Silvia, et al.
Publicado: (2022)

Distinct expression profiles and functions of Kindlins in breast cancer
por: Azorin, Paula, et al.
Publicado: (2018)

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas
por: Rème, Thierry, et al.
Publicado: (2013)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
por: Marangoni, E, et al.
Publicado: (2009)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization
por: Vallerand, David, et al.
Publicado: (2016)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture
por: Fridriksdottir, Agla J., et al.
Publicado: (2015)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma
por: Tsantoulis, Petros, et al.
Publicado: (2019)

Oestrogen deficiency modulates particle-induced osteolysis
por: Nich, Christophe, et al.
Publicado: (2011)

Nuclear and cytoplasmic oestrogen receptors in squamous carcinoma of the cervix.
por: Soutter, W. P., et al.
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_cgfh00fao1u71avqk8c4kjo16i